TY - JOUR
T1 - Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone
T2 - A preliminary study
AU - Scott, Travis M.
AU - Rivera Mindt, Monica
AU - Cunningham, Chinazo O.
AU - Arias, Franchesca
AU - Coulehan, Kelly
AU - Mangalonzo, Aprille
AU - Olsen, Pat
AU - Arnsten, Julia H.
N1 - Funding Information:
This work was supported by National Institutes of Health [R01DA032552 to MRM & JA].
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/11/15
Y1 - 2017/11/15
N2 - Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.
AB - Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.
KW - Adherence
KW - Buprenorphine/Naloxone
KW - Depression
KW - Neuropsychological change
KW - Opioid agonist treatment
KW - Opioid use disorder
UR - http://www.scopus.com/inward/record.url?scp=85034619151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034619151&partnerID=8YFLogxK
U2 - 10.1186/s13011-017-0133-2
DO - 10.1186/s13011-017-0133-2
M3 - Article
C2 - 29141650
AN - SCOPUS:85034619151
SN - 1747-597X
VL - 12
JO - Substance Abuse: Treatment, Prevention, and Policy
JF - Substance Abuse: Treatment, Prevention, and Policy
IS - 1
M1 - 48
ER -
